Who Paid My Doc
Flublok Quadrivalent Northern Hemisphere
Biological Vaccines
NDC 49281-722-10
General payments
$357,261
Research payments
$8,498,042
Through program year 2025, $357,261 in general payments and $8,498,042 in research payments were reported against Flublok Quadrivalent Northern Hemisphere (Vaccines).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $91,284 | 4,009 |
| 2025 | Research | $542,650 | 56 |
| 2024 | General | $24,839 | 1,255 |
| 2024 | Research | $836,927 | 83 |
| 2023 | General | $134,508 | 5,861 |
| 2023 | Research | $5,640,308 | 185 |
| 2022 | General | $106,523 | 2,239 |
| 2022 | Research | $1,453,411 | 29 |
| 2021 | General | $107 | 5 |
| 2021 | Research | $24,746 | 2 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 77 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
13,369 general · 355 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.